<p>Sera Prognostics（纳斯达克代码：SERA - 获取免费报告）于周三发布了季度财报。该公司报告季度每股收益为（$0.16），超出市场普遍预期的（$0.17）$0.01，FiscalAI 报道。Sera Prognostics 的净利润率为负 34,343.16%，股本回报率为负 41.69%。该季度的营业收入为 0.01 百万美元，而分析师预计为 0.03 百万美元。</p>
<p>获取 <strong>Sera Prognostics</strong> 的提醒：</p>
<h2>Sera Prognostics 价格表现</h2>
<p>周三，纳斯达克 SERA 股价下跌 $0.10，报 $1.91。该股票的交易量为 217,068 股，而其平均交易量为 59,219 股。该公司的 50 日移动平均价格为 $2.70，200 日移动平均价格为 $3.03。该股票的市值为 $7373 万，市盈率为 -2.48，贝塔系数为 1.01。Sera Prognostics 的 52 周低点为 $1.37，52 周高点为 $4.20。</p>
<h2>华尔街分析师预测增长</h2>
<p>SERA 最近成为多份研究报告的主题。杰富瑞金融集团在 12 月 15 日的研究报告中将 Sera Prognostics 的股票评级上调至 “强力买入”。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Sera Prognostics 股票的 “卖出（d-）” 评级。一位分析师给予该股票 “强力买入” 评级，另一位则给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 $5.00。</p>
<p><strong>查看我们关于 Sera Prognostics 的最新报告</strong></p>
<h2>Sera Prognostics 的内部买卖情况</h2>
<p>在其他新闻中，首席执行官 Zhenya Lindgardt 于 3 月 10 日星期二出售了 22,639 股该公司的股票。股票以平均价格 $1.90 出售，总价值为 $43,014.10。出售完成后，首席执行官持有 741,287 股公司股票，价值 $1,408,445.30。此次交易代表其持股比例下降 2.96%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接获取。在过去的九十天里，内部人士出售了价值 $115,794 的 57,133 股公司股票。公司内部人士持有 15.80% 的股份。</p>
<h2>机构投资者对 Sera Prognostics 的看法</h2>
<p>机构投资者最近增加或减少了对该公司的持股。Lido Advisors LLC 在第三季度以 $68,000 的估值收购了 Sera Prognostics 的新头寸。Cetera Investment Advisers 在第四季度以约 $74,000 的估值收购了 Sera Prognostics 的新股份。Two Sigma Investments LP 在第三季度以约 $97,000 的估值购买了 Sera Prognostics 的新头寸。Qube Research &amp; Technologies Ltd 在第二季度以约 $92,000 的估值收购了 Sera Prognostics 的新头寸。最后，巴克莱 PLC 在第四季度将其在 Sera Prognostics 的持股增加了 267.4%。巴克莱 PLC 目前持有 36,722 股公司股票，价值 $108,000，此前在该期间又购买了 26,726 股。机构投资者和对冲基金持有公司 54.64% 的股份。</p>
<h2>Sera Prognostics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Sera Prognostics, Inc 是一家精准医疗公司，专注于通过蛋白质组学检测改善妊娠结果。该公司的旗舰产品 PreTRM™ 测试是一种基于血液的检测，旨在通过测量母体血清中的特定蛋白生物标志物来评估女性早产的风险。通过识别有自发早产高风险的患者，Sera Prognostics 旨在实现更早的干预和量身定制的护理计划，从而减少与早产相关的新生儿并发症的发生率。</p>
<p>自 2014 年成立以来，Sera Prognostics 在 2020 年首次公开募股后，与美国各地的临床研究网络和产科护理提供者密切合作，以验证其 PreTRM 测试的临床表现。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Sera Prognostics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0VSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0VSQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Sera Prognostics 吗？</h2>
<p>在考虑 Sera Prognostics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Sera Prognostics 并不在名单上。</p>
<p>虽然 Sera Prognostics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

SERA

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Sera Prognostics (NASDAQ:SERA) 报告季度每股收益为（$0.16），超出预期的（$0.17）$0.01。该公司产生的收入为$0.01 百万，低于预期的$0.03 百万。Sera Prognostics 的股本回报率为负 41.69%，净利润率为负 34,343.16%。股票交易价格下跌至$1.91，市值为$73.73 百万。分析师的评级不一，包含一个强烈买入和一个卖出。机构投资者持有 54.64% 的股份，首席执行官 Zhenya Lindgardt 最近出售了价值$43,014.10 的股份</p>

<p>Sera Prognostics (NASDAQ:SERA - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01, FiscalAI reports. Sera Prognostics had a negative net margin of 34,343.16% and a negative return on equity of 41.69%. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.03 million.</p>
<div class="lb-trans"><p>Sera Prognostics（纳斯达克代码：SERA - 获取免费报告）于周三发布了季度财报。该公司报告季度每股收益为（$0.16），超出市场普遍预期的（$0.17）$0.01，FiscalAI 报道。Sera Prognostics 的净利润率为负 34,343.16%，股本回报率为负 41.69%。该季度的营业收入为 0.01 百万美元，而分析师预计为 0.03 百万美元。</p>
</div><p>Get <strong>Sera Prognostics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sera Prognostics</strong> 的提醒：</p>
</div><h2>Sera Prognostics Price Performance</h2>
<div class="lb-trans"><h2>Sera Prognostics 价格表现</h2>
</div><p>NASDAQ SERA traded down $0.10 on Wednesday, hitting $1.91. The stock had a trading volume of 217,068 shares, compared to its average volume of 59,219. The business's fifty day moving average price is $2.70 and its 200 day moving average price is $3.03. The stock has a market cap of $73.73 million, a price-to-earnings ratio of -2.48 and a beta of 1.01. Sera Prognostics has a 52-week low of $1.37 and a 52-week high of $4.20.</p>
<div class="lb-trans"><p>周三，纳斯达克 SERA 股价下跌 $0.10，报 $1.91。该股票的交易量为 217,068 股，而其平均交易量为 59,219 股。该公司的 50 日移动平均价格为 $2.70，200 日移动平均价格为 $3.03。该股票的市值为 $7373 万，市盈率为 -2.48，贝塔系数为 1.01。Sera Prognostics 的 52 周低点为 $1.37，52 周高点为 $4.20。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>SERA has been the subject of a number of recent research reports. Jefferies Financial Group raised shares of Sera Prognostics to a &#34;strong-buy&#34; rating in a research note on Monday, December 15th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Sera Prognostics in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $5.00.</p>
<div class="lb-trans"><p>SERA 最近成为多份研究报告的主题。杰富瑞金融集团在 12 月 15 日的研究报告中将 Sera Prognostics 的股票评级上调至 “强力买入”。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Sera Prognostics 股票的 “卖出（d-）” 评级。一位分析师给予该股票 “强力买入” 评级，另一位则给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 $5.00。</p>
</div><p><strong>Check Out Our Latest Report on Sera Prognostics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Sera Prognostics 的最新报告</strong></p>
</div><h2>Insider Buying and Selling at Sera Prognostics</h2>
<div class="lb-trans"><h2>Sera Prognostics 的内部买卖情况</h2>
</div><p>In other news, CEO Zhenya Lindgardt sold 22,639 shares of the firm's stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $1.90, for a total value of $43,014.10. Following the completion of the sale, the chief executive officer owned 741,287 shares of the company's stock, valued at $1,408,445.30. This trade represents a 2.96% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders sold 57,133 shares of company stock valued at $115,794. 15.80% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Zhenya Lindgardt 于 3 月 10 日星期二出售了 22,639 股该公司的股票。股票以平均价格 $1.90 出售，总价值为 $43,014.10。出售完成后，首席执行官持有 741,287 股公司股票，价值 $1,408,445.30。此次交易代表其持股比例下降 2.96%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接获取。在过去的九十天里，内部人士出售了价值 $115,794 的 57,133 股公司股票。公司内部人士持有 15.80% 的股份。</p>
</div><h2>Institutional Investors Weigh In On Sera Prognostics</h2>
<div class="lb-trans"><h2>机构投资者对 Sera Prognostics 的看法</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the business. Lido Advisors LLC acquired a new position in Sera Prognostics during the third quarter valued at $68,000. Cetera Investment Advisers acquired a new stake in Sera Prognostics during the 4th quarter worth about $74,000. Two Sigma Investments LP purchased a new position in shares of Sera Prognostics during the 3rd quarter valued at about $97,000. Qube Research &amp; Technologies Ltd acquired a new position in shares of Sera Prognostics in the 2nd quarter valued at about $92,000. Finally, Barclays PLC lifted its holdings in shares of Sera Prognostics by 267.4% in the 4th quarter. Barclays PLC now owns 36,722 shares of the company's stock valued at $108,000 after buying an additional 26,726 shares during the period. Institutional investors and hedge funds own 54.64% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了对该公司的持股。Lido Advisors LLC 在第三季度以 $68,000 的估值收购了 Sera Prognostics 的新头寸。Cetera Investment Advisers 在第四季度以约 $74,000 的估值收购了 Sera Prognostics 的新股份。Two Sigma Investments LP 在第三季度以约 $97,000 的估值购买了 Sera Prognostics 的新头寸。Qube Research &amp; Technologies Ltd 在第二季度以约 $92,000 的估值收购了 Sera Prognostics 的新头寸。最后，巴克莱 PLC 在第四季度将其在 Sera Prognostics 的持股增加了 267.4%。巴克莱 PLC 目前持有 36,722 股公司股票，价值 $108,000，此前在该期间又购买了 26,726 股。机构投资者和对冲基金持有公司 54.64% 的股份。</p>
</div><h2>Sera Prognostics Company Profile</h2>
<div class="lb-trans"><h2>Sera Prognostics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company's flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman's risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.</p>
<div class="lb-trans"><p>Sera Prognostics, Inc 是一家精准医疗公司，专注于通过蛋白质组学检测改善妊娠结果。该公司的旗舰产品 PreTRM™ 测试是一种基于血液的检测，旨在通过测量母体血清中的特定蛋白生物标志物来评估女性早产的风险。通过识别有自发早产高风险的患者，Sera Prognostics 旨在实现更早的干预和量身定制的护理计划，从而减少与早产相关的新生儿并发症的发生率。</p>
</div><p>Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.</p>
<div class="lb-trans"><p>自 2014 年成立以来，Sera Prognostics 在 2020 年首次公开募股后，与美国各地的临床研究网络和产科护理提供者密切合作，以验证其 PreTRM 测试的临床表现。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Sera Prognostics</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Sera Prognostics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0VSQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=SERA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sera Prognostics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Sera Prognostics 吗？</h2>
</div><p>Before you consider Sera Prognostics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Sera Prognostics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sera Prognostics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Sera Prognostics 并不在名单上。</p>
</div><p>While Sera Prognostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sera Prognostics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Sera Prognostics (NASDAQ:SERA) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Market Beat

Sera Prognostics

Sera Prognostics（纳斯达克代码：SERA）公布季度财报，每股收益超出预期 0.01 美元